Status:

TERMINATED

Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19

Lead Sponsor:

IGM Biosciences, Inc.

Conditions:

Healthy Volunteers

COVID-19

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics (PK) of IGM-6268 administered intranasally and intraorall...

Detailed Description

IGM-6268 is an engineered Immunoglobulin M (IgM) antibody that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. This humanized pentameric IgM antibody has 10 bin...

Eligibility Criteria

Inclusion

  • Healthy Volunteers
  • Is male or non-pregnant female adult ≥ 18 and ≤ 55 years of age
  • Has a body mass index (BMI) \< 35 kg/m2.
  • Is healthy as determined by medical history and physical examination
  • Agrees to use contraception through 3 months after the last dose of IGM-6268

Exclusion

  • Receipt of any COVID-19 vaccine during this study and follow-up period
  • Prior positive SARS-CoV2 test
  • Hepatitis B virus (HBV), hepatitis C virus (HCV), or uncontrolled human immunodeficiency virus (HIV) infection
  • Use of any nasally administered drug
  • Mild-Moderate COVID Patients
  • Inclusion Criteria:
  • Is male or non-pregnant female adult ≥ 18 and ≤ 55 years of age
  • Agrees to use contraception through 3 months after the last dose of IGM-6268
  • Agrees to the collection of blood, urine, saliva, and nasopharyngeal samples, per protocol.
  • Signs and symptoms of mild to moderate COVID-19 but not requiring hospitalization
  • Has a laboratory-confirmed SARS-CoV-2 infection as determined by FDA-authorized antigen or NAAT diagnostic assay during the period of 72 hours prior to enrollment.

Key Trial Info

Start Date :

January 20 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 4 2022

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT05184218

Start Date

January 20 2022

End Date

July 4 2022

Last Update

October 14 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Farmovs

Bloemfontein, Free State, South Africa, 9301